Core Viewpoint - Hydreight Technologies Inc. has entered into a strategic partnership with Perfect Scripts LLC, which includes acquiring a 5% interest in Perfect Scripts and establishing a 503B pharmacy in the U.S. This partnership aims to enhance Hydreight's growth by improving pharmacy margins and expanding its healthcare service offerings [2][3]. Company Overview - Hydreight Technologies Inc. operates a mobile clinical network across North America, integrating nurses, doctors, and pharmacy distribution to provide healthcare services directly to patients [14]. - Perfect Scripts LLC is the parent company of several pharmacies and holds proprietary technology, including PerfectOS, which facilitates efficient pharmacy operations [4][5]. Transaction Details - The binding letter of intent (LOI) outlines that Hydreight will acquire 5% of Perfect Scripts in exchange for 2,250,000 common shares, with a minimum deemed price of CAD$2.30 per share [2]. - The transaction includes provisions for Hydreight to maintain its pro rata interest and potentially acquire up to 40% of Perfect Scripts [2]. - A definitive agreement is expected to be finalized by August 25, 2025, subject to due diligence and regulatory approvals [9]. Strategic Implications - The partnership is expected to enhance Hydreight's control over production, distribution, and pricing of key pharmaceuticals, thereby increasing pharmacy margins and securing a consistent supply chain [3]. - The establishment of a 503B pharmacy will allow Hydreight to serve a broader market, including hospitals, clinics, and direct-to-consumer brands [3]. Operational Capacity - PerfectRx, a subsidiary of Perfect Scripts, operates as a HIPAA-compliant mail-order pharmacy capable of processing over 150,000 prescriptions daily, with plans to expand its capacity with a new location in the Dallas-Fort Worth area [5][6][7]. - The proprietary PerfectOS platform enhances operational efficiency through digital prescription intake and real-time inventory management [5][7]. Market Positioning - The partnership positions Hydreight to leverage a comprehensive legal and technology framework, enhancing its competitive edge in the healthcare market [3]. - The VSDHOne platform, developed in collaboration with Victory Square Technologies, aims to simplify the entry for businesses into the online healthcare space, offering compliant solutions for various healthcare products [15].

Core Viewpoint - Victory Square Technologies Inc. reported solid financial results for Q1 2025 and emphasized its strategic focus on the digital health and wellness sectors, identifying significant growth opportunities in a fragmented healthcare market [4][11]. Financial Highlights - Adjusted Revenue for Q1 2025 was $6.528 million, while GAAP Revenue stood at $4.540 million. The Cost of Goods Sold (COGS) was $3.036 million, resulting in a Gross Margin of $1.504 million. As of March 31, 2025, the company had Cash & Marketable Securities amounting to $9.698 million [7]. Business Focus Areas - The company aims to scale its holdings in the digital health sector, particularly through its flagship portfolio company, Hydreight Technologies, which provides a compliant platform for healthcare services across the U.S. [4][8]. - Insu Therapeutics is developing a patent-pending oral insulin tablet, with early trials showing promising results in insulin uptake [8][14]. - Pawsible Ventures is focused on pet wellness and telehealth, leveraging trends in human healthcare, with the global pet care market projected to reach $368 billion by 2030 [10][14]. Portfolio Management - Victory Square actively manages its portfolio, having sold certain AI fintech solutions for approximately $880,000 in equity consideration in Q1 2025. This follows a previous sale of BlockX for about $1.7 million in listed shares [11][15]. Industry Context - The U.S. healthcare spending exceeds $4.5 trillion annually and is projected to reach $7 trillion by 2031, highlighting the sector's fragmentation and potential for value creation [4]. - The global diabetes therapeutics market is expected to reach $118 billion by 2032, with over 500 million people currently living with diabetes [14]. Upcoming Events - Victory Square will host an Investor Webinar on July 17, 2025, to provide updates and address investor questions [12]. Leadership and Strategy - The leadership team at Insu Therapeutics includes experienced professionals from academia and the pharmaceutical industry, indicating a strong foundation for advancing its clinical milestones [14]. - The company’s business model focuses on buying, building, and investing in early-stage tech companies, with a commitment to supporting their growth for up to 48 months [17].

Core Insights - Hydreight Technologies Inc. has launched a direct-to-consumer genetic testing and personalized wellness solution through its VSDHOne platform, expanding access to precision-based care [1][2][8] Group 1: Product Offering - The new offering allows patients to access at-home DNA testing kits and receive personalized health plans based on their genetic profiles, including insights on nutrition, fitness, supplementation, and medication compatibility [2][5] - Key features of the offering include at-home DNA swab kits, lab-based genetic sequencing, personalized health recommendations, and consultations with licensed prescribers [11][12] Group 2: Market Positioning - The launch positions Hydreight's extensive network of over 3,000 nurses, 200 physicians, and 400 direct-to-consumer brands to provide this service, enhancing revenue and patient retention through personalized care [4][7] - The global consumer genomics market is projected to exceed $50 billion by 2030, with the at-home testing market expected to surpass $15 billion by 2028, indicating strong growth potential for Hydreight's new offering [6] Group 3: Business Model - The offering is structured around a subscription-based model, generating upfront revenue from testing and recurring monthly revenue from tailored health regimens and supplement delivery [9] - The integration into the VSDHOne platform allows for immediate embedding of genetic testing into existing offerings, driving higher customer retention and lifetime value [9] Group 4: Strategic Goals - Hydreight's genetic testing initiative aligns with its 2025 priorities, which include expanding high-margin white-label services, scaling onboarding of licensed direct-to-consumer brands, and launching new wellness categories [10][16]

Core Insights - Hydreight Technologies Inc. is a rapidly growing digital health platform focused on transforming mobile and telehealth services in the U.S. [1] - The company will present at two investor conferences in June 2025, showcasing its healthcare infrastructure and technology platform [1][2] - Recent financial results indicate significant growth, with adjusted revenue increasing by 31% year-over-year [6] Financial Performance - FY2024 Adjusted Revenue reached $22.32 million CAD, a 31% increase year-over-year [6] - GAAP Revenue was reported at $16.04 million CAD, reflecting a 39% year-over-year growth [6] - Adjusted EBITDA improved to +$490,000 CAD, compared to a loss of -$1.38 million CAD in FY2023 [6] - Cash Flow from Operations was positive at +$857,000 CAD, with a current cash position of $6.8 million CAD [6] Business Expansion - In 2024, Hydreight expanded its service offerings to include Liraglutide, NAD+, TRT, peptide therapies, and oral weight-loss medications [4] - The company secured strategic partnerships with national health franchises and clinical experts, enhancing its service capabilities [4] - Hydreight has sold over 400 licenses to direct-to-consumer (D2C) brands across all 50 states, indicating strong market penetration [6] Technology and Platform Development - The VSDHOne platform was developed to facilitate compliant entry for companies into the online healthcare space, significantly reducing launch time and costs [9] - Hydreight's platform supports a network of over 3,000 nurses and 200 physicians, providing a comprehensive mobile clinic network across the U.S. [8] - The platform includes integrated tools for accounting, documentation, sales, inventory, and patient data management, enhancing operational efficiency for healthcare professionals [8]

Core Insights - Hydreight Technologies Inc. has appointed Dr. Jeremy Roebuck as a director, effective May 5, 2025, following the resignation of Alexandros Tzilios [1] - Dr. Roebuck has over two decades of medical experience and has been on Hydreight's Board of Advisors since December 2022 [2][3] - His appointment is expected to enhance Hydreight's strategic initiatives, particularly in expanding its network of healthcare professionals and diversifying service offerings [7][8] Company Overview - Hydreight Technologies Inc. operates a mobile clinical network of over 2,500 nurses and 100 doctors across 50 states, providing healthcare services directly to patients [10] - The company has developed a proprietary platform that includes tools for accounting, documentation, sales, inventory, booking, and managing patient data [10] - Hydreight is recognized as the 56th fastest-growing company in North America on the 2024 Deloitte Technology Fast 500™ [9] Dr. Jeremy Roebuck's Background - Dr. Roebuck is a board-certified otolaryngologist with a subspecialty in neurotology, having completed his medical degree and residency training in Texas [3][4] - He has been in private practice since 2007 and has experience in performing advanced surgical procedures [4] - Additionally, he owns and serves as Medical Director of The Med Spa, which offers various wellness and aesthetic services [5][6] Strategic Value of Dr. Roebuck's Appointment - Dr. Roebuck's clinical and operational expertise is expected to bridge traditional healthcare and at-home wellness services, aligning with Hydreight's mission [6] - His insights into ENT and neurotology are anticipated to inform the expansion of Hydreight's service offerings [6] - The appointment is seen as a key move to enhance the company's capabilities in wellness, anti-aging, and direct-to-consumer care [8] VSDHOne Platform - Hydreight has launched the VSDHOne platform in partnership with Victory Square Technologies, aimed at simplifying entry for companies into the online healthcare space [11] - The platform offers compliant healthcare solutions, including GLP-1s, peptides, and personalized treatments, enabling businesses to launch direct-to-consumer healthcare brands quickly [11] - VSDHOne is designed to reduce the time and costs associated with launching healthcare services, allowing businesses to go live in days instead of months [11]

Core Insights - Hydreight Technologies Inc. has reported significant growth in its financial performance for the fiscal year 2024, achieving record revenues and positive Adjusted EBITDA, while focusing on scaling its VSDHOne platform for 2025 [2][6][9]. Financial Performance - The company achieved record topline revenue of CAD 22.32 million in 2024, representing a 31% increase from 2023 [6][17]. - GAAP revenue for 2024 was CAD 16.04 million, up 39% from CAD 11.51 million in 2023 [6][9]. - Adjusted EBITDA for 2024 was CAD 490,000, a turnaround from a loss of CAD 1.38 million in 2023 [6][17]. - The gross margin for 2024 was CAD 5.75 million, an increase of 8% from the previous year [6][17]. - The fourth quarter of 2024 saw revenues of CAD 4.04 million, a 20% increase compared to the same quarter in 2023 [7][9]. Strategic Focus for 2025 - The company plans to expand franchise white-label partnerships to enhance its market presence [13]. - There is a focus on increasing pharmacy margins through supply chain optimization and strategic pricing [14]. - New wellness categories will be launched, including NAD+, testosterone replacement therapy, and peptide therapies [14]. - The onboarding of high-growth D2C healthcare companies on the VSDHOne platform will be accelerated [15]. - The company aims to attract and support more licensed nurses to enhance its provider network [15]. - Strategic tuck-in acquisitions of complementary D2C health brands are being pursued to improve product mix and margins [15]. Recognition and Milestones - Hydreight was ranked 9 on Deloitte's 2024 Technology Fast 50 list and 56 on the Technology Fast 500 list for North America [6][9]. - The company completed its first post-IPO financing, raising CAD 5.4 million in February 2025 to support its growth initiatives [6][9]. Operational Highlights - The company operates a network of over 3,000 nurses and 200+ physicians across all 50 states, facilitating a scalable telehealth and at-home care model [11][12]. - Hydreight's VSDHOne platform supports over 400 Direct to Consumer license holders, enabling rapid entry into the online healthcare space [11][21].

VANCOUVER, British Columbia and LAS VEGAS, April 17, 2025 (GLOBE NEWSWIRE) -- Hydreight Technologies Inc. (TSXV: NURS) (OTCQB: HYDTF) (FSE: SO6), a fast-growing digital health platform transforming mobile and telehealth services in the U.S., today announced that it will be presenting at the Planet MicroCap Showcase: VEGAS 2025 in partnership with MicroCapClub on Wednesday, April 23, 2025 at 12:30 PM (Local Time -PST). Shane Madden (CEO of Hydreight Technologies) will be hosting the presentation and answerin ...